Table 1.
Characteristics of studies included in the individual patient data meta-analysis
| Authors (year) | Design | Population (adult/pediatric) | Number of patients | Dose of heparin | Outcomes included in IPD meta-analysis | References | |
|---|---|---|---|---|---|---|---|
| Heparin | Control | ||||||
| Holt (2008) | Retrospective with historical control | Smoke inhalation (adult and pediatric) | 62 | 88 | 30,000 | VFD-28; hospital mortality; pneumonia; PaO2/FiO2 at day 7; hospital-free days and alive at day 28 | [50] |
| Dixon (2008) | Open label phase 1 trial | Critically ill (adult) | 16 | – | 50,000–400,000 | VFD-28; ICU mortality; ICU and hospital-free days and alive at day 28 | [39] |
| Miller (2009) | Retrospective with historical control | Smoke inhalation (adult) | 16 | 14 | 60,000 | VFD-28; hospital mortality; PaO2/FiO2 and LIS at day 7; ICU and hospital-free days and alive at day 28; pneumonia | [52] |
| Dixon (2010) | Randomized controlled trial | Critically ill (adult) | 25 | 25 | 150,000 | VFD-28; hospital mortality; PaO2/FiO2 and LIS at day 7; ICU and hospital-free days and alive at day 28 | [40] |
| Kashefi (2014) | Retrospective with historical control | Smoke inhalation (adult) | 20 | 20 | 30,000 | VFD-28; hospital mortality; pneumonia; PaO2/FiO2; and hospital-free days and alive at day 28 | [51] |
VFD-28 ventilator-free days and alive at day 28, IPD individual patient data meta-analysis, LIS Lung injury scores